- ￥3939
- OriGene
- AM39048SU-N
- 美国
- 2026年04月01日
- IF, IHC
- Mouse
- Rat
企业认证
相关产品推荐更多 >
Goat Polyclonal Anti-IL-17D (aa55-65) Antibody
￥5371
Carrier-free (BSA/glycerol-free) CHN1 mouse monoclonal antibody, clone OTI2G6 (formerly 2G6)
￥3999Carrier-free (BSA/glycerol-free) MTRF1L mouse monoclonal antibody, clone OTI1H7 (formerly 1H7)
￥3999Carrier-free (BSA/glycerol-free) PDSS2 mouse monoclonal antibody, clone OTI4F9 (formerly 4F9)
￥3999HPV18 E2 protein (1-83) mouse monoclonal antibody, clone 2E7, Aff - Purified
￥5742
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
MHC Class II (non polymorphic) mouse monoclonal antibody, clone HIS28, Supernatant
- 抗体英文名：
MHC Class II (non polymorphic) mouse monoclonal antibody, clone HIS28, Supernatant
- 应用范围：
IF, IHC
- 宿主：
Mouse
- 适应物种：
Rat
- 保质期：
Stable for 12 months from date of receipt.
- 目录编号：
AM39048SU-N
- 级别：
科研级
- 库存：
5周
- 供应商：
OriGene
- 克隆性：
Monoclonal
- 保存条件：
Store undiluted at 2-8°C.
- 形态：
State: SupernatantState: Liquid cell culture supernatant containing 0.09% sodium azide
- 规格：
1 ml
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Identification of MHC Class II Binding Peptides: Microarray and Soluble MHC Class II Molecules
binding peptides. We present here a high content screening for MHC class II (HLA-DR) binding to a peptide library in a chip-format. Binding of soluble MHC class II molecules to individual peptides can be visualized using an anti-DR directed monoclonal
of mouse spleen DCs by Flt3L treatment and immunoprecipitation of MHC II-peptide complexes), mass spectrometry analysis and peptide synthesis (LC-MS/MS and quantitation analysis for non tryptic peptides) to identify and quantitate the endogenous peptides
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
